E. Joline de Groof

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial

Cyriel Y. Ponsioen, E. Joline de Groof, Emma J. Eshuis et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 356 citations

Medicine, Clinical Sciences, Surgery +12

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial

Toer Stevens, Maria L. Haasnoot, Geert D’Haens et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 179 citations

Medicine, Surgery, Gastroenterology +10

Treatment of Perianal Fistulas in Crohn’s Disease, Seton Versus Anti-TNF Versus Surgical Closure Following Anti-TNF [PISA]: A Randomised Controlled Trial

K Wasmann, E. Joline de Groof, M E Stellingwerf et al. · Journal of Crohn s and Colitis · 2020 · 116 citations · Full text

Medicine, Clinical Sciences, Surgery +15

Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C Trial

E. Joline de Groof, Toer Stevens, Emma J. Eshuis et al. · Gut · 2019 · 103 citations · Full text

Pharmacy, Pharmacoeconomics, Surgery +16

Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands

E. Joline de Groof, Noortje Rossen, Bram D. van Rhijn et al. · European Journal of Gastroenterology & Hepatology · 2016 · 72 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12